LT3143011T - Deuterinti heterocikliniai junginiai ir jų naudojimas kaip vaizdinimo agentų - Google Patents
Deuterinti heterocikliniai junginiai ir jų naudojimas kaip vaizdinimo agentųInfo
- Publication number
- LT3143011T LT3143011T LTEP15725253.7T LT15725253T LT3143011T LT 3143011 T LT3143011 T LT 3143011T LT 15725253 T LT15725253 T LT 15725253T LT 3143011 T LT3143011 T LT 3143011T
- Authority
- LT
- Lithuania
- Prior art keywords
- heterocyclic compounds
- deuterated
- imagining agents
- imagining
- deuterated heterocyclic
- Prior art date
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Optics & Photonics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461992717P | 2014-05-13 | 2014-05-13 | |
| PCT/EP2015/060447 WO2015173225A1 (en) | 2014-05-13 | 2015-05-12 | Deuterated heterocyclic compounds and their use as imaging agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT3143011T true LT3143011T (lt) | 2021-05-10 |
Family
ID=53269446
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEP15725253.7T LT3143011T (lt) | 2014-05-13 | 2015-05-12 | Deuterinti heterocikliniai junginiai ir jų naudojimas kaip vaizdinimo agentų |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US10076581B2 (2) |
| EP (2) | EP3901145A1 (2) |
| JP (2) | JP6529986B2 (2) |
| KR (2) | KR102530129B1 (2) |
| CN (2) | CN106459059B (2) |
| AU (2) | AU2015261008B2 (2) |
| CA (1) | CA2948721C (2) |
| DK (1) | DK3143011T3 (2) |
| ES (1) | ES2867814T3 (2) |
| HR (1) | HRP20210641T1 (2) |
| HU (1) | HUE053939T2 (2) |
| IL (3) | IL280791B2 (2) |
| LT (1) | LT3143011T (2) |
| MX (2) | MX376163B (2) |
| PL (1) | PL3143011T3 (2) |
| PT (1) | PT3143011T (2) |
| RS (1) | RS61810B1 (2) |
| RU (1) | RU2696492C2 (2) |
| SG (2) | SG10201805628TA (2) |
| SI (1) | SI3143011T1 (2) |
| WO (1) | WO2015173225A1 (2) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE053939T2 (hu) | 2014-05-13 | 2021-08-30 | Hoffmann La Roche | Deuterált heterociklikus vegyületek és képalkotó kontrasztanyagként való használatuk |
| WO2018015546A1 (en) | 2016-07-22 | 2018-01-25 | Ac Immune S.A. | Compounds for imaging tau protein aggregates |
| KR102472003B1 (ko) | 2016-07-22 | 2022-11-29 | 에이씨 이뮨 에스에이 | 타우 단백질 응집체를 이미징하기 위한 화합물 |
| MX2019005007A (es) * | 2016-11-01 | 2019-07-18 | Arvinas Inc | Protac dirigidos a la proteína tau y métodos asociados de uso. |
| AU2018346597B2 (en) | 2017-10-06 | 2023-07-13 | Forma Therapeutics, Inc. | Inhibiting Ubiquitin Specific Peptidase 30 |
| EP3743423A1 (en) | 2018-01-24 | 2020-12-02 | AC Immune SA | Gamma-carboline compounds for the detection of tau aggregates |
| US20210041447A1 (en) | 2018-01-24 | 2021-02-11 | Ac Immune Sa | Azacarboline compounds for the detection of tau aggregates |
| US11623927B2 (en) | 2018-03-02 | 2023-04-11 | The Trustees Of The University Of Pennsylvania | Substituted [1,2,4]triazolo[1,5-a]pyrimidines for stabilizing microtubules |
| JP7449242B2 (ja) | 2018-05-17 | 2024-03-13 | フォーマ セラピューティクス，インコーポレイテッド | ユビキチン特異的ペプチダーゼ３０（ｕｓｐ３０）阻害剤として有用な縮合二環化合物 |
| JP7297053B2 (ja) | 2018-08-20 | 2023-06-23 | アルビナス・オペレーションズ・インコーポレイテッド | 神経変性疾患を治療するためのｅ３ユビキチンリガーゼ結合活性を有するキメラ（ｐｒｏｔａｃ）化合物を標的とし、アルファ－シヌクレインタンパク質を標的とするタンパク質分解 |
| CR20210175A (es) | 2018-09-18 | 2021-06-01 | Nikang Therapeutics Inc | Derivados de anillo tricíclico condensado como inhibidores de la fosfatasa de homología a src 2 (shp2) |
| JP7530889B2 (ja) | 2018-10-05 | 2024-08-08 | フォーマ セラピューティクス，インコーポレイテッド | ユビキチン特異的プロテアーゼ３０（ｕｓｐ３０）阻害剤として作用する縮合ピロリン |
| MX2021003904A (es) | 2018-10-05 | 2021-10-26 | Annapurna Bio Inc | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor apj. |
| TWI767148B (zh) | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | 抑制脂肪酸合成酶(fasn) |
| JP7119978B2 (ja) * | 2018-12-20 | 2022-08-17 | オムロン株式会社 | 制御装置およびプログラム |
| MX2021013574A (es) * | 2019-05-09 | 2021-12-10 | Hoffmann La Roche | Sintesis de imidazo[1,2-a]pirimidinas etiquetadas. |
| EP3999182A1 (en) | 2019-07-17 | 2022-05-25 | Arvinas Operations, Inc. | Tau-protein targeting compounds and associated methods of use |
| CN113526526A (zh) * | 2021-07-12 | 2021-10-22 | 苏州大学 | 氘代氨制备方法及以其作为氘源参与的氘代反应 |
| JP2024534151A (ja) | 2021-08-27 | 2024-09-18 | ジェネンテック， インコーポレイテッド | タウ病態の治療方法 |
| CN120187452A (zh) | 2022-06-13 | 2025-06-20 | 基因泰克公司 | 使用克瑞尼珠单抗延迟或预防阿尔茨海默病的发作的方法 |
| WO2025155625A1 (en) * | 2024-01-16 | 2025-07-24 | Eli Lilly And Company | Novel compounds for tau imaging |
| CN118957609B (zh) * | 2024-07-23 | 2025-09-09 | 无锡绿能电合科技有限公司 | 一种氟代芳环的氘代方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE76515C (de) | F. MORA in Mailand | Verfahren zur Herstellung imitirter Ledertapete aus Baumwollstoff | ||
| DD76515A (2) * | ||||
| EP1340759A1 (en) | 2002-02-28 | 2003-09-03 | Sanofi-Synthelabo | 1-[alkyl], 1-[(heteroaryl)alkyl] and 1-[(aryl)alkyl]-7-(pyrimidin-4-yl)-imidazo[1,2-a]pyrimidin-5(1H)-one derivatives |
| US6875784B2 (en) | 2002-10-09 | 2005-04-05 | Pharmacia & Upjohn Company | Antimibicrobial [3.1.0.] bicyclic oxazolidinone derivatives |
| PL1999109T3 (pl) * | 2006-03-30 | 2012-05-31 | Univ Pennsylvania | Pochodne styrylopirydyny i ich zastosowanie do wiązania i obrazowania blaszek amyloidowych |
| MX2010002692A (es) * | 2007-09-13 | 2010-06-01 | Concert Pharmaceuticals Inc | Sintesis de catecoles deuterados y derivados de benzo[d][1,3]dioxoles de los mismos. |
| EP2247558B2 (en) | 2008-02-14 | 2024-07-03 | Eli Lilly and Company | Novel imaging agents for detecting neurological dysfunction |
| US8932557B2 (en) | 2008-02-14 | 2015-01-13 | Eli Lilly And Company | Imaging agents for detecting neurological dysfunction |
| US20100144657A1 (en) * | 2008-12-09 | 2010-06-10 | Auspex Pharmaceuticals, Inc. | PHENYLPIPERIDINE MODULATORS OF mu-OPIOID RECEPTORS |
| JP2012521988A (ja) | 2009-03-23 | 2012-09-20 | シーメンス メディカル ソリューションズ ユーエスエー インコーポレイテッド | 神経学的障害を検知するためのイメージング剤 |
| US8691187B2 (en) | 2009-03-23 | 2014-04-08 | Eli Lilly And Company | Imaging agents for detecting neurological disorders |
| EP2450332A1 (en) | 2010-10-22 | 2012-05-09 | Bayer Pharma Aktiengesellschaft | Compounds for use in Imaging, diagnosing and/or treatment of diseases of the central nervous system (F-D2-Deprenyl) |
| KR20140003438A (ko) * | 2010-11-15 | 2014-01-09 | 카톨리에케 유니버시테이트 루벤 | 항바이러스성 축합 헤테로사이클릭 화합물 |
| CN104781234A (zh) * | 2012-05-22 | 2015-07-15 | 伊莱利利公司 | 用于检测神经功能障碍的基于咔啉和咔唑的成像剂 |
| CN105358558B (zh) * | 2013-10-08 | 2017-09-26 | 豪夫迈·罗氏有限公司 | 作为tau‑pet‑配体的二氮杂咔唑衍生物 |
| HUE053939T2 (hu) | 2014-05-13 | 2021-08-30 | Hoffmann La Roche | Deuterált heterociklikus vegyületek és képalkotó kontrasztanyagként való használatuk |
-
2015
- 2015-05-12 HU HUE15725253A patent/HUE053939T2/hu unknown
- 2015-05-12 PL PL15725253T patent/PL3143011T3/pl unknown
- 2015-05-12 LT LTEP15725253.7T patent/LT3143011T/lt unknown
- 2015-05-12 PT PT157252537T patent/PT3143011T/pt unknown
- 2015-05-12 AU AU2015261008A patent/AU2015261008B2/en active Active
- 2015-05-12 HR HRP20210641TT patent/HRP20210641T1/hr unknown
- 2015-05-12 SG SG10201805628TA patent/SG10201805628TA/en unknown
- 2015-05-12 KR KR1020167034871A patent/KR102530129B1/ko active Active
- 2015-05-12 RS RS20210532A patent/RS61810B1/sr unknown
- 2015-05-12 KR KR1020237006997A patent/KR102618139B1/ko active Active
- 2015-05-12 SG SG11201609281UA patent/SG11201609281UA/en unknown
- 2015-05-12 CN CN201580025219.XA patent/CN106459059B/zh active Active
- 2015-05-12 DK DK15725253.7T patent/DK3143011T3/da active
- 2015-05-12 SI SI201531590T patent/SI3143011T1/sl unknown
- 2015-05-12 CA CA2948721A patent/CA2948721C/en active Active
- 2015-05-12 JP JP2016567651A patent/JP6529986B2/ja active Active
- 2015-05-12 CN CN201910795177.8A patent/CN110483522B/zh active Active
- 2015-05-12 ES ES15725253T patent/ES2867814T3/es active Active
- 2015-05-12 WO PCT/EP2015/060447 patent/WO2015173225A1/en not_active Ceased
- 2015-05-12 MX MX2016014615A patent/MX376163B/es active IP Right Grant
- 2015-05-12 IL IL280791A patent/IL280791B2/en unknown
- 2015-05-12 MX MX2020010847A patent/MX384604B/es unknown
- 2015-05-12 EP EP21155891.1A patent/EP3901145A1/en active Pending
- 2015-05-12 EP EP15725253.7A patent/EP3143011B1/en active Active
- 2015-05-12 RU RU2016147742A patent/RU2696492C2/ru active
-
2016
- 2016-01-26 US US15/006,997 patent/US10076581B2/en active Active
- 2016-11-01 IL IL248692A patent/IL248692B/en active IP Right Grant
-
2018
- 2018-07-31 US US16/050,453 patent/US10675367B2/en active Active
-
2019
- 2019-05-14 AU AU2019203369A patent/AU2019203369B2/en active Active
- 2019-05-15 JP JP2019091813A patent/JP6681498B2/ja active Active
- 2019-12-22 IL IL271631A patent/IL271631B/en active IP Right Grant
-
2020
- 2020-06-08 US US16/895,352 patent/US11504440B2/en active Active
-
2022
- 2022-11-18 US US18/056,856 patent/US12214058B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LT3143011T (lt) | Deuterinti heterocikliniai junginiai ir jų naudojimas kaip vaizdinimo agentų | |
| LT3317284T (lt) | Benzoksazepino oksazolidinono junginiai ir jų naudojimo būdai | |
| LT3221306T (lt) | Heteroarilo junginiai, kaip irak inhibitoriai ir jų panaudojimas | |
| LT3102555T (lt) | Junginių kompozicijos ir jų panaudojimas | |
| GB201403093D0 (en) | Therapeutic compounds and their use | |
| LT2970303T (lt) | Pakeistieji ksantinai ir jų panaudojimo metodai | |
| HRP20190432T1 (hr) | Spojevi pladienolid piridina i postupci uporabe | |
| LT3129019T (lt) | Artemizinino junginių ir gefirino agonistų medicininis panaudojimas | |
| PL3194421T3 (pl) | Związki cytotoksyczne i przeciwmitotyczne oraz sposoby ich wykorzystania | |
| LT3197898T (lt) | Nauji imidazopiridazino junginiai ir jų panaudojimas | |
| HUE054245T2 (hu) | Immunszupresszáns formuláció | |
| IL251904B (en) | Apilimod for use in the treatment of melanoma | |
| DK3193840T3 (da) | Arimoclomol-formulering | |
| PT3212237T (pt) | Formulação de metotrexato | |
| LT3231793T (lt) | Dihidropirimidin-2-ono junginiai ir jų medicininis panaudojimas | |
| IL264445A (en) | Compounds and compositions and uses thereof | |
| CL2016002705A1 (es) | Formulación agroquímica | |
| DK3148513T3 (da) | Ceritinib-formulering | |
| EP3181125C0 (en) | CAPSULE FORMULATION | |
| FR3021528B1 (fr) | Formulation cosmetique | |
| DK3193856T3 (da) | Formulering | |
| ES1119005Y (es) | Prenda reversible desmontable | |
| LT3518927T (lt) | 1-fenilpropanono junginiai ir jų panaudojimas | |
| TH1701000764A (th) | สูตรผสมฆ่าเชื้อและการใช้งานของสูตรผสมนั้น | |
| TH1501005156A (th) | สารประกอบเฮทเทอโรไซคลิก และการใช้ของสารเหล่านี้ |